SomaLogic announces agreement to deploy SOMAscan assay at NIH Center
SomaLogic, Inc. announced today that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan™ proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015, under the leadership of CHI Director Neal S. Young, M.D.
“CHI’s mission is to perform cooperative research based on advanced technologies in order to efficiently translate enhanced understanding of immune function and pathophysiology to the clinic,” said Dr. Young. “We believe the SOMAscan assay gives us a powerful new tool to open up proteomics research and biomarker discovery to many more NIH scientists who are performing a wide variety of critical preclinical and clinical studies.”
Compared to other current proteomic technologies, SomaLogic’s offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic’s proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measure proteins across a wide range of concentrations in small volumes of multiple biological sample types.
“We are delighted to partner with NIH to give its world-class researchers access to the SOMAscan assay,” said Byron Hewett, Chief Executive Officer of SomaLogic. “CHI’s commitment to applying our technology to critical biomedical questions will help ensure the accelerated discovery of new biomarkers – and potentially new therapeutic approaches – for many different diseases.”
SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to CHI, include Massachusetts General Hospital and the University of Pennsylvania, with several more expected to be announced in the coming weeks.
The trans-NIH CHI is sponsored by the National Cancer Institute, the
National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis, Musculoskeletal and Skin Diseases, the National Institute of Child Health and Human Development, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, the National Institute of Environmental Health Sciences, the National Eye Institute, the National Human Genome Research Institute, and the Food and Drug Administration. For more information about CHI, please visit